HSE Warns Of Significant Skin Cancer Increase Into The Future - Tipperary Mid West Radio tippmidwestradio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tippmidwestradio.com Daily Mail and Mail on Sunday newspapers.
Date Time
Study finds vitamin D does not protect against most cancers
QIMR Berghofer researchers have found vitamin D levels do not influence a person’s risk of developing most common cancers, suggesting that widespread use of vitamin D supplements is unlikely to prevent cancer.
The study used genetic markers of vitamin D to examine the relationship between vitamin D and endometrial, ovarian, oesophageal, prostate, pancreatic and lung cancers, as well as neuroblastoma, melanoma, and basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin.
While they did not find a link between most of the cancers, the researchers did confirm previous research that found women who were genetically predisposed to having higher levels of vitamin D had a slightly lower risk of developing ovarian cancer.
Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 An Investigator-Initiated Trial Will Run in Parallel YAVNE, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer. MediWound recently submitted a protocol to the FDA for a phase I/II clinical study of MWPC005 for the treatment of basal cell carcinoma (BCC) and is preparing to initiate this study in the United States in the second quarter of 2021. A phase II investigator-initiated trial of MWPC005 in non-melanoma skin cancer will be conducted in parallel at the Soroka Medical Center in Israel. MediWound expects that data from both studies will be generated
Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of STP705 for the treatment of isSCC, as well as to analyze biomarkers common to isSCC formation pathways
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
December 20, 2020 GMT
Sirnaomics Company Logo (PRNewsfoto/Sirnaomics, Inc.)
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen’s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of S